Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | PTEN negative |
| Therapy | Abiraterone + Capivasertib + Prednisone |
| Indication/Tumor Type | prostate cancer |
| Response Type | sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| PTEN negative | prostate cancer | sensitive | Abiraterone + Capivasertib + Prednisone | FDA approved - On Companion Diagnostic | Actionable | In a Phase III trial (CAPItello-281) that supported FDA approval, addition of Truqap (capivasertib) to Zytiga (abiraterone), Adasone (prednisone), and androgen deprivation therapy significantly improved radiographic progression-free survival (33.2 vs 25.7 mo, HR 0.81, p=0.034) compared to placebo in patients with PTEN-deficient (>/=90% tumor cells with no cytoplasmic PTEN by IHC) metastatic hormone-sensitive prostate cancer (PMID: 41120017; NCT04493853). | detail... 41120017 detail... |
| PubMed Id | Reference Title | Details |
|---|---|---|
| Full reference... | ||
| Truqap (capivasertib) FDA Drug Label | Full reference... | |
| (41120017) | Capivasertib plus abiraterone in PTEN-deficient metastatic hormone-sensitive prostate cancer: CAPItello-281 phase III study. | Full reference... |